Canadian Cancer Trials Group Bulletins

General


Recent Publications

PA.3 - A Randomized Placebo Controlled Study of OSI-774 Plus Gemcitabine in Patients with Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

Vickers MM, Lee C, Tu D, Wheatley-Price P, Parulekar W, Brundage MD, Moore MJ, Au H, O'Callaghan CJ, Jonker DJ, Ringash J, Goldstein D. Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. Pancreatology 16: 1106-12, 2016.

http://www.sciencedirect.com/science/article/pii/S1424390316311814
_______________________________

MAC.5/IBCSG 25-02 - A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer

Johansson H, Gray KP, Pagani O, Regan MM, Viale G, Aristarco V, Macis D, Puccio A, Roux S, Maibach R, Colleoni M, Rabaglio M, Price KN, Coates AS, Gelber RD, Goldhirsch A, Kammler R, Bonanni B, Walley BA. Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Breast Cancer Research 18: 110, 2016.

https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-016-0771-8